Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes
for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an
industrial scale since 2005 to make these special sugars available for
affordably priced infant formula and other uses in food. Jennewein
Biotechnologie was the first commercial vendor of HMOs, and brought the HMO
2'-fucosyllactose for the first time on the market in 2015.

The Danish company Glycom A/S initially tried to chemically synthesize HMOs, but
now imitates the path of biotechnological manufacturing of HMOs as pursued by
Jennewein Biotechnologie from the beginning.

"After Glycom failed for a decade to accomplish the chemical synthesis, as well
as possible biotechnological attempts to produce HMOs at reasonable costs and in
industrially relevant amounts, we became aware by Glycom's recent EFSA and FSANZ
filings that they are imitating Jennewein's processes and infringing our
intellectual property." said Dr. Stefan Jennewein, CEO of Jennewein
Biotechnologie GmbH. "We will enforce our intellectual property rights against
Glycom and will not tolerate this outrageous patent infringement." adds Dr.
Andreas Hübel, Director IP of Jennewein Biotechnologie GmbH.

Jennewein Biotechnologie has already obtained a seizure order against Glycom and
additional evidence seized which will further substantiate infringement of
Jennewein's European Patent EP 2 896 628 B1, and requested an interlocutory
injunction against the manufacturing and offering of Glycom's HMO products in
Denmark on basis of its Danish utility model DK 2019 00054. "Besides the
infringement of said patent, we see a number of additional infringements of our
IPRs by Glycom." said Dr. Andreas Hübel.

About HMOs:

Human milk oligosaccharides (HMOs) are complex sugar molecules that are only
present in breast milk. Excluding water, they are the third most abundant
constituent of human milk after fats and lactose. More than 200 structurally
different HMOs have been identified.

The most abundant HMO is 2'-fucosyllactose, which is produced by about 80% of
all lactating mothers at concentrations of up to 3 g/L. Scientific studies have
shown that HMOs, and 2'fucosyllactose in particular, have a positive impact on
infant development. HMOs are prebiotic, i.e. they specifically promote the
growth of beneficial microorganisms, and at the same time they inhibit the
growth of pathogens by directly and indirectly preventing colonisation.
Jennewein Biotechnologie launched 2'-fucosyllactose onto the global baby food
market in 2015, and several infant milk formula around the world now contain
2'-fucosyllactose.

About Jennewein Biotechnologie:

Jennewein Biotechnologie is a leading international industrial biotechnology
company with a range of products in the field of human milk oligosaccharides
(HMOs) and rare monosaccharides such as L-Fucose and Sialic acid. The company
manufactures an extensive portfolio of innovative HMO products, such as
2'fucosyllactose, 3'-fucosyllactose, Lacto-N-neotetraose, and lacto-N-tetraose.
These rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry. The
manufacturing process involves state-of-the-art fermentation techniques. In
2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie
a license to market 2'-fucosyllactose in the USA. This was followed in 2017 by
European Union marketing authorisation under the Novel Food Regulation.

Contact:
Dr. Bettina Gutiérrez
Bettina.gutierrez@jennewein-biotech.de
Tel.:+49 2224 98810 797

Additional content: https://www.presseportal.de/pm/77411/4449160
OTS: Jennewein Biotechnologie GmbH

Original-Content von: Jennewein Biotechnologie GmbH, übermittelt durch news aktuell